세계의 당뇨병성 신장 질환 시장 보고서(2025년)

Diabetic kidney disease is a form of renal disease resulting from complications of diabetes, where elevated blood sugar levels lead to kidney damage. The kidneys' blood vessels can be adversely affected by high blood glucose, reducing their functionality.

The primary types of diabetic kidney disease are associated with both type 1 and type 2 diabetes. Type 1 diabetes is a chronic autoimmune condition characterized by minimal or no insulin production by the pancreas. This deficiency leads to elevated blood sugar levels, causing damage to the nephrons and renal blood vessels. Managing blood sugar levels in type 1 diabetes often requires daily insulin injections. Treatment for diabetic kidney disease includes interventions such as angiotensin receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, antioxidant inflammation modulators, calcium channel blockers, and other medical approaches provided in facilities such as hospitals, homecare, specialty centers, and more.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The diabetic kidney disease market research report is one of a series of new reports from The Business Research Company that provides diabetic kidney disease market statistics, including global market size, regional shares, competitors with a diabetic kidney disease market share, detailed diabetic kidney disease market segments, market trends and opportunities, and any further data you may need to thrive in the diabetic kidney disease industry. This diabetic kidney disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The diabetic kidney disease market size has grown steadily in recent years. It will grow from $2.67 billion in 2024 to $2.8 billion in 2025 at a compound annual growth rate (CAGR) of 4.8%. The growth in the historic period can be attributed to early understanding of diabetes complications, advancements in diagnostic techniques, development of ace inhibitors and arbs, clinical trials and treatment protocols, guidelines and disease management protocols.

The diabetic kidney disease market size is expected to see strong growth in the next few years. It will grow to $3.53 billion in 2029 at a compound annual growth rate (CAGR) of 6.0%. The growth in the forecast period can be attributed to personalized medicine and biomarker development, rising global diabetes incidence, focus on disease modification therapies, telehealth and remote care, healthcare policy and reimbursement changes. Major trends in the forecast period include advancements in renal replacement therapies, precision medicine approach, focus on early detection and diagnosis, therapeutic advancements, rise in comorbidities management.

The forecast of 6.0% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. nephrology practices by driving up the cost of SGLT2 inhibitors and renal anemia drugs sourced from the UK and Japan, exacerbating chronic kidney disease management expenses. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The rising prevalence of chronic kidney disease is anticipated to drive the growth of the diabetic kidney disease market. Chronic kidney disease (CKD) is a long-term condition that leads to a gradual loss of kidney function, resulting in various complications such as high blood pressure, anemia, and bone diseases. Treating chronic kidney diseases necessitates diagnostic and treatment options, which ultimately fuels the expansion of the diabetic kidney disease market. For instance, in June 2023, Kidney Research UK, a prominent charity in the UK, reported that chronic kidney disease affects approximately 7.2 million people in the United Kingdom, representing over 10% of the population. Among these individuals, 3.25 million are in the most severe stages of the disease, while around 3.9 million are in the early stages, which are often untreated and asymptomatic. Projections suggest that the total number of individuals with chronic kidney disease in the United Kingdom could rise to 7.61 million by 2033. Thus, the increasing prevalence of chronic kidney disease is propelling the growth of the diabetic kidney disease market.

The growing healthcare expenditure is expected to enhance the growth of the diabetic kidney disease market in the future. Healthcare expenditure refers to the total funds allocated for healthcare-related goods and services within a specific timeframe, typically at a national or institutional level. Increased healthcare spending promotes the adoption of advanced diagnostic technologies, enabling early and accurate detection of diabetic kidney disease and facilitating timely intervention and treatment. For example, in May 2023, the Office for National Statistics, a UK-based government department, reported that healthcare spending in the UK rose by 5.6% between 2022 and 2023, compared to a growth rate of 0.9% in 2022. The UK healthcare expenditure was approximately £292 billion in 2023. Therefore, the rising healthcare expenditure is driving the growth of the diabetic kidney disease market.

Technological advancements emerge as a pivotal trend gaining traction in the diabetic kidney disease market. Companies within this sector embrace novel technologies to fortify their market standing. For instance, in August 2022, Bloom Diagnostics, a US-based organization specializing in diagnostics and healthcare devices, introduced the Bloom Kidney Test. Integrated with the Bloom Smart System, this diagnostic tool evaluates kidney health by measuring cystatin C levels-a reliable indicator of kidney function. Categorizing kidney function into three stages-normal, mildly decreased, and decreased-the Bloom Kidney Test leverages cloud-based algorithms and AI technology within the Bloom Smart System. This integration combines test outcomes with pertinent health data such as medical history, lifestyle, and patient symptoms, facilitating comprehensive analysis and management.

Leading companies in the diabetic kidney disease market are actively innovating by developing new products such as medications tailored for chronic kidney disease (CKD), aiming for wider customer reach, increased sales, and revenue growth. These medications for CKD primarily focus on symptom management, slowing disease progression, and addressing complications arising from impaired kidney function. For instance, Bayer AG, a Germany-based pharmaceutical company, introduced Kerendia in August 2022-a medication specifically designed to manage CKD associated with diabetes. Kerendia stands out as a non-steroidal, selective mineralocorticoid receptor antagonist, uniquely tailored for individuals with chronic kidney disease linked to type-II diabetes. Offering a distinctive treatment approach, Kerendia holds promise in slowing CKD progression and reducing the risk of kidney failure in this susceptible patient group.

In January 2023, AstraZeneca, a UK-based biotech and pharmaceutical giant, finalized the acquisition of Cincor Pharma Inc. for an undisclosed sum. This strategic move strengthens AstraZeneca's cardiorenal pipeline by integrating CinCor's baxdrostat (CIN-107), an aldosterone synthase inhibitor (ASI) aimed at lowering blood pressure in treatment-resistant hypertension. Cincor Pharma Inc., a US-based biopharmaceutical company, specializes in developing drugs for kidney disease management. AstraZeneca's acquisition bolsters its portfolio by incorporating innovative solutions such as baxdrostat, further solidifying its position in addressing cardiorenal complications and advancing therapeutic options for kidney disease management.

Major companies operating in the diabetic kidney disease market include AstraZeneca plc, Pfizer Inc., Novartis AG, Bayer AG, Sanofi SA, Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Company, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Fresenius SE & Co. KGaA, F. Hoffmann-La Roche AG, Abbott Laboratories, Reata Pharmaceuticals Inc., Merck & Co., Mitsubishi Tanabe Pharma Corporation, Johnson & Johnson pvt. Ltd., Eli Lilly and Company, GlaxoSmithKline plc, AbbVie Inc., Boehringer Ingelheim International GmbH, Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Company Limited

North America was the largest region in the diabetic kidney disease market in 2024. The regions covered in the diabetic kidney disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the diabetic kidney disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The diabetic kidney disease market includes revenues earned by entities by providing diabetic kidney disease treatments for kidney stones, kidney infection, polycystic kidney disease, and kidney cysts. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Diabetic Kidney Disease Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on diabetic kidney disease market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for diabetic kidney disease ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The diabetic kidney disease market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Type 1 Diabetes; Type 2 Diabetes
• 2) By Treatment: Angiotensin Receptor Blockers (Arbs); Angiotensin-Converting Enzyme (Ace) Inhibitors; Antioxidant Inflammation Modulator; Calcium Channel Blockers; Other Treatments
• 3) By End User: Hospitals; Homecare; Specialty Centers; Other End Users
• Subsegments:
• 1) By Type 1 Diabetes: Autoimmune-Related Diabetic Kidney Disease; Early-Onset Diabetic Kidney Disease
• 2) By Type 2 Diabetes: Obesity-Related Diabetic Kidney Disease; Late-Onset Diabetic Kidney Disease
• Companies Mentioned: AstraZeneca plc; Pfizer Inc.; Novartis AG; Bayer AG; Sanofi SA; Teva Pharmaceutical Industries Ltd.; Bristol-Myers Squibb Company; Sun Pharmaceutical Industries Ltd.; Aurobindo Pharma Ltd.; Fresenius SE & Co. KGaA; F. Hoffmann-La Roche AG; Abbott Laboratories; Reata Pharmaceuticals Inc.; Merck & Co.; Mitsubishi Tanabe Pharma Corporation; Johnson & Johnson pvt. Ltd.; Eli Lilly and Company; GlaxoSmithKline plc; AbbVie Inc.; Boehringer Ingelheim International GmbH; Chugai Pharmaceutical Co. Ltd.; Daiichi Sankyo Company Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Diabetic Kidney Disease Market Characteristics

3. Diabetic Kidney Disease Market Trends And Strategies

4. Diabetic Kidney Disease Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Diabetic Kidney Disease Growth Analysis And Strategic Analysis Framework

• 5.1. Global Diabetic Kidney Disease PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Diabetic Kidney Disease Market Growth Rate Analysis
• 5.4. Global Diabetic Kidney Disease Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Diabetic Kidney Disease Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Diabetic Kidney Disease Total Addressable Market (TAM)

6. Diabetic Kidney Disease Market Segmentation

• 6.1. Global Diabetic Kidney Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Type 1 Diabetes
• Type 2 Diabetes
• 6.2. Global Diabetic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Angiotensin Receptor Blockers (Arbs)
• Angiotensin-Converting Enzyme (Ace) Inhibitors
• Antioxidant Inflammation Modulator
• Calcium Channel Blockers
• Other Treatments
• 6.3. Global Diabetic Kidney Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Speciality Centres
• Other End Users
• 6.4. Global Diabetic Kidney Disease Market, Sub-Segmentation Of Type 1 Diabetes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Autoimmune-Related Diabetic Kidney Disease
• Early-Onset Diabetic Kidney Disease
• 6.5. Global Diabetic Kidney Disease Market, Sub-Segmentation Of Type 2 Diabetes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Obesity-Related Diabetic Kidney Disease
• Late-Onset Diabetic Kidney Disease

7. Diabetic Kidney Disease Market Regional And Country Analysis

• 7.1. Global Diabetic Kidney Disease Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Diabetic Kidney Disease Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Diabetic Kidney Disease Market

• 8.1. Asia-Pacific Diabetic Kidney Disease Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Diabetic Kidney Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Diabetic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Diabetic Kidney Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Diabetic Kidney Disease Market

• 9.1. China Diabetic Kidney Disease Market Overview
• 9.2. China Diabetic Kidney Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Diabetic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Diabetic Kidney Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Diabetic Kidney Disease Market

• 10.1. India Diabetic Kidney Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Diabetic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Diabetic Kidney Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Diabetic Kidney Disease Market

• 11.1. Japan Diabetic Kidney Disease Market Overview
• 11.2. Japan Diabetic Kidney Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Diabetic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Diabetic Kidney Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Diabetic Kidney Disease Market

• 12.1. Australia Diabetic Kidney Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Diabetic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Diabetic Kidney Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Diabetic Kidney Disease Market

• 13.1. Indonesia Diabetic Kidney Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Diabetic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Diabetic Kidney Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Diabetic Kidney Disease Market

• 14.1. South Korea Diabetic Kidney Disease Market Overview
• 14.2. South Korea Diabetic Kidney Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Diabetic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Diabetic Kidney Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Diabetic Kidney Disease Market

• 15.1. Western Europe Diabetic Kidney Disease Market Overview
• 15.2. Western Europe Diabetic Kidney Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Diabetic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Diabetic Kidney Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Diabetic Kidney Disease Market

• 16.1. UK Diabetic Kidney Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Diabetic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Diabetic Kidney Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Diabetic Kidney Disease Market

• 17.1. Germany Diabetic Kidney Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Diabetic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Diabetic Kidney Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Diabetic Kidney Disease Market

• 18.1. France Diabetic Kidney Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Diabetic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Diabetic Kidney Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Diabetic Kidney Disease Market

• 19.1. Italy Diabetic Kidney Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Diabetic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Diabetic Kidney Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Diabetic Kidney Disease Market

• 20.1. Spain Diabetic Kidney Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Diabetic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Diabetic Kidney Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Diabetic Kidney Disease Market

• 21.1. Eastern Europe Diabetic Kidney Disease Market Overview
• 21.2. Eastern Europe Diabetic Kidney Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Diabetic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Diabetic Kidney Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Diabetic Kidney Disease Market

• 22.1. Russia Diabetic Kidney Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Diabetic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Diabetic Kidney Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Diabetic Kidney Disease Market

• 23.1. North America Diabetic Kidney Disease Market Overview
• 23.2. North America Diabetic Kidney Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Diabetic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Diabetic Kidney Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Diabetic Kidney Disease Market

• 24.1. USA Diabetic Kidney Disease Market Overview
• 24.2. USA Diabetic Kidney Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Diabetic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Diabetic Kidney Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Diabetic Kidney Disease Market

• 25.1. Canada Diabetic Kidney Disease Market Overview
• 25.2. Canada Diabetic Kidney Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Diabetic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Diabetic Kidney Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Diabetic Kidney Disease Market

• 26.1. South America Diabetic Kidney Disease Market Overview
• 26.2. South America Diabetic Kidney Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Diabetic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Diabetic Kidney Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Diabetic Kidney Disease Market

• 27.1. Brazil Diabetic Kidney Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Diabetic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Diabetic Kidney Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Diabetic Kidney Disease Market

• 28.1. Middle East Diabetic Kidney Disease Market Overview
• 28.2. Middle East Diabetic Kidney Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Diabetic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Diabetic Kidney Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Diabetic Kidney Disease Market

• 29.1. Africa Diabetic Kidney Disease Market Overview
• 29.2. Africa Diabetic Kidney Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Diabetic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Diabetic Kidney Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Diabetic Kidney Disease Market Competitive Landscape And Company Profiles

• 30.1. Diabetic Kidney Disease Market Competitive Landscape
• 30.2. Diabetic Kidney Disease Market Company Profiles
  • 30.2.1. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis

31. Diabetic Kidney Disease Market Other Major And Innovative Companies

• 31.1. Teva Pharmaceutical Industries Ltd.
• 31.2. Bristol-Myers Squibb Company
• 31.3. Sun Pharmaceutical Industries Ltd.
• 31.4. Aurobindo Pharma Ltd.
• 31.5. Fresenius SE & Co. KGaA
• 31.6. F. Hoffmann-La Roche AG
• 31.7. Abbott Laboratories
• 31.8. Reata Pharmaceuticals Inc.
• 31.9. Merck & Co.
• 31.10. Mitsubishi Tanabe Pharma Corporation
• 31.11. Johnson & Johnson pvt. Ltd.
• 31.12. Eli Lilly and Company
• 31.13. GlaxoSmithKline plc
• 31.14. AbbVie Inc.
• 31.15. Boehringer Ingelheim International GmbH

32. Global Diabetic Kidney Disease Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Diabetic Kidney Disease Market

34. Recent Developments In The Diabetic Kidney Disease Market

35. Diabetic Kidney Disease Market High Potential Countries, Segments and Strategies

• 35.1 Diabetic Kidney Disease Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Diabetic Kidney Disease Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Diabetic Kidney Disease Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer